Sidewinder Therapeutics
Agent51 out of 100, Top 25%. Agent Readiness. Open the scores section.Agent Readiness: 51/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust77 out of 100, Above median. Data Trust. Open the scores section.Data Trust: 77/100. Above median. Measured by StartupHub.ai. Median 61.Pioneering next-generation bispecific ADCs for cancer treatment.
About
Sidewinder Therapeutics is pioneering the next generation of bispecific antibody-drug conjugates (ADCs) designed to expand the therapeutic window for patients with difficult-to-treat cancers. Their engineered ADCs target receptor co-complexes highly expressed on solid tumors, aiming for enhanced tumor cell specificity and internalization. The company is built by a team of entrepreneurs, scientists, and drug developers committed to delivering these advanced therapies.
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Pharmaceuticals
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
Shares Biotechnology, Drug Discovery
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- sidewinderbio.com
- Headquarters
- San Diego, California, USA
- Founded
- 2026
- Employees
- 9
- Total funding
- $137M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 8 Apr 2026 | Series B | $137M | Frazier Life Sciences, Novartis Venture Fund |
Tech stack
Detected on sidewinderbio.com, last scanned 9 Nov 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- SEO
- All in One SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Mimecast
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Sidewinder Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Sidewinder Therapeutics is 77 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Sidewinder Therapeutics raised?
Sidewinder Therapeutics has raised a total of $137M in funding. The most recent round on record is Series B.
How many employees does Sidewinder Therapeutics have?
Sidewinder Therapeutics has approximately 9 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Sidewinder Therapeutics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
